About this trial
This project will target patients with highly clinically suspected or histopathology diagnosed hepatocellular carcinoma (HCC) using targeted GPC3-specific imaging agents (e.g. , Iodine-131-aGPC3-Scfv) for integrated SPECTCT imaging, to evaluate the pharmacokinetics distribution of the targeted drug in patients with hepatocellular carcinoma (HCC) by low-dose integrated diagnosis and treatment (i.e. , Iodine-131-RRB- imaging, to determine the metabolism, safety and tolerability of the drug in vivo Secondary objective: to evaluate the targeting of GPC3-SPECIFIC imaging agents in patients with hepatocellular carcinoma to assess the feasibility of this targeted agent for future treatment.
Eligibility criteria
Qualifiers
the subject or his/her legal representative can sign and date the informed consent form
commitment to follow the research procedures and cooperate in the implementation of the full-process research
patients with high clinical suspicion or histopathology diagnosis of HCC and generally in good condition
patients with a history of hepatocellular carcinoma who recur after treatment
Disqualifiers
inability to complete SPECTCT examination (including inability to lie down, claustrophobia, radiophobia, etc.)
acute systemic diseases and electrolyte disorders
patients with known hypersensitivity to GPC3 imaging agents or synthetic excipients
patients considered by the investigator to have poor adherence
Trial design
Treatments tested in this trial
- 131I-aGPC3